TEL AVIV, Israel and BETHESDA, Maryland, Aug. 10, 2018 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that its CEO, Mr. Eyal Barad, will be attending the Benzinga Cannabis Capital Conference, to be held at the Toronto Arcadian Centre, on August 16th-17th 2018, and will be available for one on one meetings.
The Cannabis Capital Conference is presented by Benzinga, a leading financial media outlet with extensive coverage of the cannabis space. It is a premier gathering of cannabis entrepreneurs and investors in North America.
Benzinga is a financial media outlet that empowers investors with unique content that is recognized by Wall Street traders. Benzinga provides ideas that help navigate the markets – in real-time.
Cannabics Pharmaceuticals' CEO was recently featured on Benzinga in an interview by Javier Hasse. The interview can be found here: Four Questions With Cannabics Pharmaceuticals CEO Eyal Barad.
More recent articles in which Cannabics was featured, that include additional information on our activities, may be seen on the new website.
Eyal Barad, CEO of the company, said: "The Benzinga Capital Conference offers a unique opportunity to meet and network with Medical Cannabis influencers and policymakers in North America, which hold great potential for future collaborations on various activities. Our goal is to thoroughly explore these potentials".
Meeting requests can be sent to: info@Cannabics.com
About Cannabics Pharmaceuticals Inc.
Cannabics Pharmaceuticals Inc. (CNBX), a U.S based public company, is dedicated to the development of Personalized Anti-Cancer and Palliative treatments. The Company's R&D is based in Israel, where it is licensed by the Ministry of Health for its work in both scientific and clinical research. The Company's focus is on harnessing the therapeutic properties of natural Cannabinoid formulations and diagnostics. Cannabics engages in developing individually tailored natural therapies for cancer patients, utilizing advanced screening systems and personalized bioinformatics tools.
Certain statements contained in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-Q Report filed on January 17th, 2017. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time.
Finally, the investing public is reminded that the only announcements or information about Cannabics Pharmaceuticals Inc. which are condoned by the Company must emanate from the Company itself, and bear our name as its Source.
For Further Information, please contact: